[Department of Error] Department of Error
Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393: 31–39—In Figures 1–5, the format has been changed so that the columns for the treatment and placebo group depict the number of patients in each group. The web appendix has also been updated. These corrections have been made to the online version as of Jan 3, 2019, and the printed version is correct.